middle.news
ReNerve Reports 79% Sales Growth and Advances Nerve Guide Matrix Development
10:34am on Thursday 30th of April, 2026 AEST
•
Healthcare
Read Story
ReNerve Reports 79% Sales Growth and Advances Nerve Guide Matrix Development
10:34am on Thursday 30th of April, 2026 AEST
Key Points
79% quarterly sales growth with first $100K+ sales month
Regulatory approvals secured in Malaysia and Hong Kong
NervAlign Nerve Guide Matrix advances to Stage 3 targeting FDA submission
Closing cash at $3.32 million with ongoing R&D investment
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Renerve (ASX:RNV)
OPEN ARTICLE